Overview of Actinogen Medical's recent quarterly activity report and Appendix 4C

Actinogen Medical (ASX: $ACW) has released its June 2024 quarterly activity report and Appendix 4C, highlighting positive results from the Xanamem® phase 2a biomarker trial. The trial demonstrated potential treatment effects in patients with Alzheimer's disease, with participants showing rapid progression in key clinical endpoints. Additionally, the XanaCIDD phase 2a clinical trial activities have concluded, and the XanaMIA phase 2b clinical trial start-up progress is underway.

Executive commentary on recent developments

Actinogen CEO, Dr. Steven Gourlay, expressed anticipation for the results of the XanaCIDD phase 2a trial, emphasizing its robust, placebo-controlled nature and the potential to improve cognition in patients with major depressive disorder. Dr. Gourlay also acknowledged the company's financial position, with significant funding sources and the anticipation of a higher R&D rebate for FY2024.

Summary of quarterly report and future outlook

Actinogen Medical's quarterly report highlights the positive Xanamem® phase 2a biomarker trial results, indicating a potential treatment effect in Alzheimer's disease patients. The company's financial position remains stable, with significant funding sources and anticipated higher R&D rebate for FY2024. Looking ahead, Actinogen Medical aims to report the results of the XanaCIDD phase 2a trial and continue the XanaMIA phase 2b clinical trial, focusing on the development of Xanamem® as a therapy for Alzheimer's disease and depression.